Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis.
Activation of coagulation and fibrinolysis within tumour tissues is thought to be associated with tumour growth, angiogenesis, and metastasis. The plasma levels of markers of thrombin and plasmin generation are sensitive tools for monitoring activation of coagulation and fibrinolysis. We studied 47 patients with histologically confirmed lung cancer, 15 with small cell (SCLC) and 32 with non-small cell lung cancer (NSCLC). The plasma levels of the following markers were assessed:thrombin-antithrombin III complex (TAT), prothrombin activation fragment F1 + 2, plasmin-alpha 2-antiplasmin complex (PAP) and the split product from cross-linked fibrin, D-dimer. The first sample was obtained before receiving any specific antineoplastic treatment. The patients were followed thereafter until treatment was terminated. There was no difference in activation markers between patients with SCLC and NSCLC. Comparing patients with limited disease to those with extensive disease, there were significant differences in TAT (median 3.0 (1.9-9.8) vs 5.3 (1.8-35.6) micrograms/l,P = 0.021) and D-dimer (569 (135-1948) vs 1288 (120-2221) micrograms/l, P = 0.014). According to the response to subsequent treatment, those who achieved complete or partial tumour remission had significantly lower baseline levels samples than non-responders (TAT 2.9 (1.9-4.0) vs 4.7 (1.8-35.6) micrograms/l,P = 0.0047;D-dimer 527 (135-1149) vs 1242 (120-2221) micrograms/l, P = 0.0013). Thus, the increase of TAT and D-dimer appears to be related to tumour spread. The results suggest that high levels of these markers might be a sign of unfavourable prognosis in patients with lung cancer.(ABSTRACT TRUNCATED AT 250 WORDS)
Department of Internal Medicine, Philipps University Hospitals, Marburg, Germany.
R
R
Seitz
N
N
Rappe
M
M
Kraus
A
A
Immel
M
M
Wolf
M
M
Maasberg
R
R
Egbring
R
R
Pfab
K
K
Havemann
D000230:Adenocarcinoma / Q000097:blood / Q000473:pathology; D000990:Antithrombin III / Q000032:analysis*; D001777:Blood Coagulation / Q000502:physiology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000473:pathology; D018288:Carcinoma, Small Cell / Q000097:blood / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000473:pathology; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D005342:Fibrinolysis; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D010447:Peptide Hydrolases / Q000032:analysis*; D011379:Prognosis; D011446:Prospective Studies
D005338:Fibrin Fibrinogen Degradation Products; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D010447:Peptide Hydrolases